- Home
- AVIR vs OLMA Comparison
AVIR vs OLMA Comparison
Compare AVIR & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- OLMA
- Stock Information
- Founded
- AVIR 2012
- OLMA 2006
- Country
- AVIR United States
- OLMA United States
- Employees
- AVIR N/A
- OLMA N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- OLMA Health Care
- Exchange
- AVIR Nasdaq
- OLMA Nasdaq
- Market Cap
- AVIR 277.8M
- OLMA 299.7M
- IPO Year
- AVIR 2020
- OLMA 2020
- Fundamental
- Price
- AVIR $3.50
- OLMA $5.51
- Analyst Decision
- AVIR Hold
- OLMA Strong Buy
- Analyst Count
- AVIR 1
- OLMA 5
- Target Price
- AVIR $6.00
- OLMA $24.00
- AVG Volume (30 Days)
- AVIR 361.0K
- OLMA 538.5K
- Earning Date
- AVIR 08-07-2025
- OLMA 08-11-2025
- Dividend Yield
- AVIR N/A
- OLMA N/A
- EPS Growth
- AVIR N/A
- OLMA N/A
- EPS
- AVIR N/A
- OLMA N/A
- Revenue
- AVIR N/A
- OLMA N/A
- Revenue This Year
- AVIR N/A
- OLMA N/A
- Revenue Next Year
- AVIR N/A
- OLMA N/A
- P/E Ratio
- AVIR N/A
- OLMA N/A
- Revenue Growth
- AVIR N/A
- OLMA N/A
- 52 Week Low
- AVIR $2.46
- OLMA $2.86
- 52 Week High
- AVIR $4.15
- OLMA $13.93
- Technical
- Relative Strength Index (RSI)
- AVIR 48.71
- OLMA 63.06
- Support Level
- AVIR $3.33
- OLMA $4.47
- Resistance Level
- AVIR $3.60
- OLMA $5.58
- Average True Range (ATR)
- AVIR 0.16
- OLMA 0.35
- MACD
- AVIR -0.02
- OLMA 0.03
- Stochastic Oscillator
- AVIR 26.69
- OLMA 87.39
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.